Hexarelin
Synthetic hexapeptide growth hormone secretagogue with documented cardiac receptor activity.
At a glance
What it is: Synthetic hexapeptide growth hormone secretagogue with documented cardiac receptor activity..
Primary research applications:
- GH/IGF-1 axis research
- Cardiac receptor biology
- Body composition (off-label)
Editorial summary: Hexarelin is one of the better-characterized GH-releasing peptides (GHRPs) in human pharmacology, with published data on GH stimulation and a distinctive line of cardiac research. Its modern role is mostly as a research tool — overshadowed in clinical use by ipamorelin and CJC-1295 combinations — but its biology remains influential.
- Class / structure
- Synthetic hexapeptide GHRP
- Half-life
- ≈ 55 minutes
- First described
- 1990s
- Regulatory status
- Not FDA-approved; research-grade only
What is Hexarelin?
Hexarelin is a synthetic hexapeptide with the structure His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2. It belongs to the growth hormone secretagogue (GHS) family, which also includes GHRP-1, GHRP-2, GHRP-6, and ipamorelin.
Discovery and development
Hexarelin was developed in the 1990s as part of the original GHRP family alongside GHRP-6 and GHRP-2. Italian groups including Imbimbo, Ghigo, and Locatelli published extensively on its endocrine and cardiovascular effects, establishing both its potency as a GH releaser and its activity at cardiac receptors that became part of the broader story of ghrelin and the GHS-R receptor.
Mechanism of action
Hexarelin acts on the GHS-R1a receptor (the same receptor as endogenous ghrelin), stimulating pulsatile GH release from the pituitary. Distinct from some other GHRPs, hexarelin has well-characterized cardiac receptor activity — binding sites in cardiac tissue that may be related to but distinct from GHS-R1a, with cardioprotective effects in rodent ischemia-reperfusion models.[1]
Pharmacokinetics
Hexarelin is administered subcutaneously, intranasally, or intravenously in research protocols. Plasma half-life is approximately 55 minutes, with peak GH responses occurring within the first hour after administration.
What the research shows
The peer-reviewed literature on Hexarelin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Stimulates GH release in humans | Multiple controlled studies | Supported |
| Has direct cardiac effects independent of GH | Animal data robust; translational data limited | Promising |
| Builds substantial muscle mass on its own | Limited human body-composition data | Uncertain |
| Causes desensitization with chronic use | Documented in repeat-dosing studies | Supported |
Reported user experiences
How the research describes administration
Research has used subcutaneous, intranasal, and intravenous routes. Modern user communities have largely shifted to ipamorelin and other selective GH secretagogues to avoid hexarelin's cortisol/prolactin side-effect profile.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Hexarelin's lasting value has been scientific rather than clinical — it helped illuminate the cardiac GHS-R-related signaling pathway and remains a useful research tool. In contemporary GH-axis peptide use, it has largely been displaced by more selective agents like ipamorelin.
Frequently asked questions
How does hexarelin compare to ipamorelin?
Both stimulate GH release via GHS-R1a. Hexarelin produces larger GH peaks but also significant cortisol and prolactin elevation; ipamorelin is more selective. Modern protocols generally favor ipamorelin for that reason.
Is hexarelin a peptide hormone?
It is a synthetic hexapeptide that mimics ghrelin's action on the GH secretagogue receptor — not a naturally occurring hormone but a pharmacological mimic.
References
- Locatelli V, et al. Cardioprotection by GH-releasing peptides. Endocr Rev. 1999;20(2):149-176. https://pubmed.ncbi.nlm.nih.gov/10204116/
- Imbimbo BP, et al. Pharmacokinetics and pharmacodynamics of hexarelin. Eur J Clin Pharmacol. 1994;46(5):421-425. https://pubmed.ncbi.nlm.nih.gov/7957535/